Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration

Overview of attention for article published in International Journal of Retina and Vitreous , February 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#20 of 268)
High Attention Score compared to outputs of the same age (86th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 1 news outlet

twitter: 2 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 11 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 200 followers.

Study shows that patients w/ neovascular age-related #maculardegeneration (#nAMD) who had shorter treatment intervals and switched to #brolucizumab treatment are more likely to have successful injection interval extension. From @biomedicalcentral https://t

03 Aug 2023

Reply Repost Favourite

Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration https://t.co/wZRSOwXOsb

02 Feb 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.